Business · 15/04/2011Updated: 10/17/2026 · 1 min read
FDA Corrects Notice on ATRYN Patent Extension Review Period
Summary
The FDA is correcting a notice that incorrectly stated the regulatory review period for ATRYN, a biologic medication, due to an error in the docket number, which was published in the Federal Register on March 21, 2011.
Original source language: Federal Register — Health and Human ServicesOpen original release →